Clinical Trials Update

Advances, Sequencing Challenges, and Real-World Integration of ADCs in Breast Cancer: Insights from ASCO 2026

Datopotamab deruxtecan: First TROP2-Directed ADC Approved for First-Line Treatment of mTNBC in Patients Ineligible for Immunotherapy

Becotatug Vedotin: First EGFR-Targeted ADC Approved in China for Recurrent or Metastatic Nasopharyngeal Carcinoma

This year, the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting will feature a breadth of new data on emerging antibody-drug conjugates (ADCs) and T-cell engagers (TCEs), particularly across solid tumors and hematologic malignancies. This article synthesizes pivotal findings from AbbVie’s next-generation ADC and TCE platforms—including SEZ6-, PSMA/STEAP1-, c-Met-, and FRα-targeted ADCs—alongside immune checkpoint inhibitor combinations and real-world evidence.

AACR 2026: Emerging Antibody-Drug Conjugates for the Treatment of Solid Tumors (Part 1)

NEOK002 (previously known as ABL209) is a novel, bispecific ADC designed to simultaneously target two key cancer antigens—Epidermal Growth Factor Receptor (EGFR), a key oncogenic driver in multiple tumor types, and Mucin-1 (MUC1), a tumor-associated antigen characterized by aberrant glycosylation and overexpression.

Pfizer has discontinued development of its early-stage immune-stimulating antibody conjugate (ISAC) PF-08046037, an investigational therapy targeting PD-L1, as part of a strategic realignment of its oncology pipeline. The decision, described as being for 'strategic business reasons' and not due to safety or efficacy concerns, comes after a series of notable clinical successes and high-profile deals that have reshaped Pfizer’s approach to cancer drug development.

Rakuten Medical is Developing ASP-1929 photoimmunotherapy Based on the Alluminox® Platform as a Selective Cancer Treatment with Focused Local Control

Recent advances in antibody-drug conjugate (ADC) technology have enabled the development of highly potent, tumor-targeted therapeutics with improved efficacy and safety. Sutro Biopharma, leveraging its site-specific and cell-free protein synthesis platform, has reported robust preclinical data for its pipeline of next-generation ADCs at the annual meeting of the American Association for Cancer Research (AACR), held April 17 - 22, 2026.

Recent Advances in the Clinical Development of First- and Best-in-Class Antibody-Drug Conjugates: Pipeline Update from Adcendo